Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Synergism between Enhanced Late Inward Currents and Tissue Fibrosis in the Initiation of Spontaneous Ventricular Tachyarrhythmias.

Karagueuzian HS.

J Heart Health. 2016 Mar;2(2). doi: 10.16966/2379-769X.120. No abstract available.

2.

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.

Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ.

BMC Cancer. 2016 Mar 2;16:176. doi: 10.1186/s12885-016-2162-z.

3.

The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction.

Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM.

J Mol Cell Cardiol. 2016 Feb;91:114-22. doi: 10.1016/j.yjmcc.2015.12.024. Epub 2015 Dec 29. Review.

4.

Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Adegunsoye A, Levy M, Oyenuga O.

Biomed Res Int. 2015;2015:929170. doi: 10.1155/2015/929170. Epub 2015 Oct 25. Review.

5.

Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling.

Horn MA, Trafford AW.

J Mol Cell Cardiol. 2016 Apr;93:175-85. doi: 10.1016/j.yjmcc.2015.11.005. Epub 2015 Nov 11. Review.

6.

The effects of remodeling with heart failure on mode of initiation of ventricular fibrillation and its spatiotemporal organization.

Everett TH 4th, Hulley GS, Lee KW, Chang R, Wilson EE, Olgin JE.

J Interv Card Electrophysiol. 2015 Sep;43(3):205-15. doi: 10.1007/s10840-015-0016-2. Epub 2015 May 23.

7.

Cardiac fibrosis as a determinant of ventricular tachyarrhythmias.

Morita N, Mandel WJ, Kobayashi Y, Karagueuzian HS.

J Arrhythm. 2014 Dec 1;30(6):389-394.

8.

Atherosclerosis exacerbates arrhythmia following myocardial infarction: Role of myocardial inflammation.

De Jesus NM, Wang L, Herren AW, Wang J, Shenasa F, Bers DM, Lindsey ML, Ripplinger CM.

Heart Rhythm. 2015 Jan;12(1):169-78. doi: 10.1016/j.hrthm.2014.10.007. Epub 2014 Oct 7.

9.

Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia.

Hong T, Yang H, Zhang SS, Cho HC, Kalashnikova M, Sun B, Zhang H, Bhargava A, Grabe M, Olgin J, Gorelik J, Marbán E, Jan LY, Shaw RM.

Nat Med. 2014 Jun;20(6):624-32. doi: 10.1038/nm.3543. Epub 2014 May 18.

10.

Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Rahmutula D, Marcus GM, Wilson EE, Ding CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ, Olgin JE.

Cardiovasc Res. 2013 Sep 1;99(4):769-79. doi: 10.1093/cvr/cvt074. Epub 2013 Apr 23.

11.

Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias.

Karagueuzian HS, Nguyen TP, Qu Z, Weiss JN.

Front Physiol. 2013 Feb 15;4:19. doi: 10.3389/fphys.2013.00019. eCollection 2013.

12.

Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy?

Karagueuzian HS.

Am J Cardiovasc Dis. 2011;1(2):101-9. Epub 2011 Jun 12.

13.

In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y.

PLoS One. 2011;6(11):e28134. doi: 10.1371/journal.pone.0028134. Epub 2011 Nov 23.

14.

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Gan Y, Herzog EL, Gomer RH.

Ther Clin Risk Manag. 2011 Feb 8;7:39-47. doi: 10.2147/TCRM.S12209.

Supplemental Content

Support Center